department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

CG Oncology, Inc. ($CGON) · pharmadog

PUBLIC COMPANY

$CGONCG Oncology, Inc.

Dallas, TX, USupdated 2h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

1

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 3

cretostimogene grenadenorepvec

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial B…

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view CG Oncology, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$CGON

SEC CIK

0001991792

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

CG Oncology, Inc. earnings

CG Oncology, Inc.

Active trials

—An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGavailable
phase2Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCrecruitingn=325
phase2Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancerwithdrawn
phase3Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerinactive not recruitingn=190
phase3A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTactive not recruitingn=367
phase2Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerincompletedn=35

Data sources

last refreshed 1m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Insider activity

source: SEC Form 4

90d open-market buys

$0

0 transactions

90d open-market sells

$1.14M

1 transaction

net (buys − sells)

−$1.14M

non-derivative only

open-market buys + sells

Apr 17, 26SELLMulay James· director15,600 sh @ $73.01−$1.14M↗
Mar 16, 26SELLMulay James· director1,310 sh @ $63.50−$83K↗
Mar 16, 26SELLMulay James· director654 sh @ $63.50−$42K↗

routine RSU / option mechanics (6)

Apr 17, 26option exerciseMulay James · director15,600 sh
Apr 17, 26option exerciseMulay James · director15,600 sh
Apr 15, 26grantKasturi Vijay · Chief Medical Officer79,216 sh
Apr 15, 26grantPatterson Joshua F. · See Remarks45,266 sh
Apr 15, 26grantDETORE JAMES M. · Chief Financial Officer90,574 sh
Apr 15, 26

grant

Kuan Arthur · Chief Executive Officer

271,600 sh

$CGON69.70-0.94%

$CGON69.70-0.94%